The development of next-generation albumin preparation by mutagenesi s studies
The development of next-generation albumin preparation by mutagenesi s studies
批准号:
14370759
负责人:
OTAGIRI Masaki
金额:
$8.58万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (B)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Human serum albumin(HSA) has many essential functions for homeostasis, such as the maintenance of osmotic pressure, drug binding and antioxidant activity. Mutagenesis studies of HSA made it possible to examine the participation of various amino acid residues and domains in the functional properties of HSA, such as binding capacity, antioxidant activity and prolonged half-life.In this study, firstly, we studied the antioxidant properties of single-residue mutants of human serum albumin. Cysteine residues, especially ^<166>Cys contribute much to this function of albumin. Secondly, Pichia pastoris has been used to express each of the three rHSA domains separately. Recombinant domain I protein exhibited antioxidant activity comparable to that of rHSA. A novel domain exchange HSA with potentially high antioxidant activity was designed where three domain I proteins of HSA were genetically fused. This exchanged HSA had higher antioxidant activity than wild-type HSA. Thirdly, rHSA dimer has been expressed using Pichia pastoris. The structure and binding capacity of rHSA dimer was almost identical to that of native HSA. rHSA dimer was shown to exhibit better intravascular retention and lower vascular permeability properties. Lastly, single-residue mutants R410C efficiently introduced NO further than the wild type. S-NO-R410C had higher antibacterial activity than S-NO-HSA.The results of this research serve as important fundamental data for further development of new recombinant albumin.
期刊论文(78)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
中城圭介, 小田切優樹(他4名): "The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants"Biochimica Biophysica Acta. 1623. 88-97 (2003)
Keisuke Nakagi、Yuki Odagiri(以及其他 4 人):“重组突变体揭示的糖基化对人血清白蛋白的结构、功能和生物命运的影响”Biochimica Biophysicala Acta。1623. 88-97 (2003)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
櫻井祐治, 小田切優樹(他6名): "Esterase-like activity of serum albumin : Characterization of its structural chemistry using p-nitrophenyl esters as substrates"Pharmaceutical Research. 21. 285-292 (2004)
Yuji Sakurai、Yuki Odagiri(其他 6 名):“血清白蛋白的酯酶样活性:使用对硝基苯酯作为底物表征其结构化学”Pharmaceutical Research 21. 285-292 (2004)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
安楽 誠, 小田切優樹(他5名): "Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo"Pharmaceutical Research. 20. 684-692 (2003)
Makoto Anraku、Yuki Odagiri(以及其他 5 人):“氯胺-T 诱导的人血清白蛋白氧化作为体内氧化损伤模型的验证”药物研究 20. 684-692 (2003)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
N-acetyl-L-cysteine and albumin through the formation of mixed disulfides in human and rat serum in vitro.
N-乙酰基-L-半胱氨酸与白蛋白在体外人和大鼠血清中形成混合二硫化物。
DOI:
--
发表时间:
2002
期刊:
Pharmaceutical Research 19
影响因子:
--
作者:
[Harada D, Naito S, Otagiri M.]
通讯作者:
Otagiri M.
DOI:
10.1023/a:1020749211745
发表时间:
2002-11-01
期刊:
PHARMACEUTICAL RESEARCH
影响因子:
3.7
作者:
[Harada, D, Naito, S, Otagiri, M]
通讯作者:
Otagiri, M
共 24 条
Development of novel hybrid anti-oxidant based on albumin fusion technology and its therapeutic application on acute radiation syndrome
-
批准号:15K15008
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.41万
-
财政年份:2015
-
负责人:OTAGIRI Masaki
-
依托单位:
Construction of an Innovative Bone Marrow Delivery System of Anticancer Drug for Control of Malignant Tumors' Bone Metastasis
-
批准号:25670085
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.5万
-
财政年份:2013
-
负责人:OTAGIRI Masaki
-
依托单位:
Design and Evaluation of Next Generation Albumin-thioredoxin Fusion Protein for Multiple Organ Failure Treatment
-
批准号:24390043
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.06万
-
财政年份:2012
-
负责人:OTAGIRI Masaki
-
依托单位:
Development of effective blood purification treatment method usingHSA bound toxic comnpodus designed bpyhase display tecnohlogy
-
批准号:23659088
-
项目类别:Grant-in-Aid for Challenging Exploratory Research
-
资助金额:$2.33万
-
财政年份:2011
-
负责人:OTAGIRI Masaki
-
依托单位:
Development of Redox Controlling Nanomedicine Based on Albumin Fusion
-
批准号:21390177
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$12.23万
-
财政年份:2009
-
负责人:OTAGIRI Masaki
-
依托单位:
Application of functional recombinant HSAs as a DDS carrier
-
批准号:18390051
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$11.09万
-
财政年份:2006
-
负责人:OTAGIRI Masaki
-
依托单位:
Design and Evaluation of Albumin Mutants for Clinical Application
-
批准号:11694298
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$4.67万
-
财政年份:1999
-
负责人:OTAGIRI Masaki
-
依托单位:
Design and Functional Evaluation of Albumin Mutants for Improving Medicinal Efficacy
-
批准号:10557245
-
项目类别:Grant-in-Aid for Scientific Research (B).
-
资助金额:$6.85万
-
财政年份:1998
-
负责人:OTAGIRI Masaki
-
依托单位:
Topology Analysis of Drug Binding Sites on Serum Proteins using Photoaffinity Labeling Techniques
-
批准号:09470505
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$7.17万
-
财政年份:1997
-
负责人:OTAGIRI Masaki
-
依托单位:
Development of Pharmaceutical Additives-Evaluation of Protein and Polysaccharide Hydrolysates as Carrier to Enhance Absorption Rate of Drug
-
批准号:07557146
-
项目类别:Grant-in-Aid for Scientific Research (B)
-
资助金额:$2.37万
-
财政年份:1995
-
负责人:OTAGIRI Masaki
-
依托单位:
Microenviromental Analysis of Drug Binding Site on Albumin by Point-mutation and Using Probe
-
批准号:06672146
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.54万
-
财政年份:1994
-
负责人:OTAGIRI Masaki
-
依托单位:
Microenvironmental Analysis of Drug Binding Sites on Human Serum Albumin and alpha_1-Acid Glycoprotein
-
批准号:02807196
-
项目类别:Grant-in-Aid for General Scientific Research (C)
-
资助金额:$1.02万
-
财政年份:1990
-
负责人:OTAGIRI Masaki
-
依托单位:
海外基金